World stocks slump amid US car bailout concerns

February 17, 2009 17:38


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


World stock markets slumped Tuesday as investors lost confidence in governments' ability to turn around the flagging global economy with expensive rescue plans. In Europe, the FTSE 100 index of British shares was down 121.52 points, or 2.9 percent, at 4,013.23, while Germany's DAX was 145.67 points, or 3.3 percent, lower at 4,220.97. The CAC-40 in France fell 74.48 points, or 2.5 percent, to 2,906.46. In the US, investors returned from their long weekend in downbeat mood. The Dow Jones industrial average tumbled 258.54 points, or 3.3 percent, soon after the open to 7,591.87, while the broader Standard & Poor's 500 index slid 32.35 points, or 3.9 percent, to 794.49.World stocks slump amid US car bailout concerns

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection